HAEM5:Primary cutaneous follicle centre lymphoma - Revision history

Bailey.Glen at 17:27, 3 July 2025

2025-07-03T17:27:31Z

← Older revision		Revision as of 12:27, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:47, 25 May 2025

2025-05-25T21:47:49Z

← Older revision		Revision as of 16:47, 25 May 2025
Line 166:		Line 166:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 241:		Line 241:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 285:		Line 285:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:23, 25 May 2025

2025-05-25T20:23:18Z

← Older revision		Revision as of 15:23, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:44, 24 March 2025

2025-03-24T17:44:52Z

← Older revision		Revision as of 12:44, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Primary cutaneous follicle centre lymphoma}}		{{DISPLAYTITLE:Primary cutaneous follicle centre lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG		Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T17:51:59Z

Removed old template contents

Show changes

Bailey.Glen at 18:58, 10 February 2025

2025-02-10T18:58:28Z

Show changes

Bailey.Glen at 18:30, 10 February 2025

2025-02-10T18:30:26Z

← Older revision		Revision as of 13:30, 10 February 2025
Line 72:		Line 72:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*Usually solitary, firm, and erythematous to violaceous plaques, nodules or tumors of variable size		*Usually solitary, firm, and erythematous to violaceous plaques, nodules or tumors of variable size
Line 79:		Line 79:
	*The skin surface is usually smooth and rarely ulcerated<ref name=":2" />		*The skin surface is usually smooth and rarely ulcerated<ref name=":2" />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 118:		Line 121:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}</blockquote>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 138:		Line 141:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==
Line 162:		Line 168:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	The t(14;18)(q32;q21), ''IGH''/''BCL2'' translocation, the genetic hallmark of nodal follicular lymphoma, is rare in primary cutaneous follicle center lymphoma<ref name=":0">{{Cite journal\|last=Gángó\|first=Ambrus\|last2=Bátai\|first2=Bence\|last3=Varga\|first3=Martin\|last4=Kapczár\|first4=Dóra\|last5=Papp\|first5=Gergő\|last6=Marschalkó\|first6=Márta\|last7=Kuroli\|first7=Enikő\|last8=Schneider\|first8=Tamás\|last9=Csomor\|first9=Judit\|date=2018-10\|title=Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein\|url=https://pubmed.ncbi.nlm.nih.gov/29858685\|journal=Virchows Archiv: An International Journal of Pathology\|volume=473\|issue=4\|pages=453–462\|doi=10.1007/s00428-018-2384-3\|issn=1432-2307\|pmid=29858685}}</ref><ref>{{Cite journal\|last=Goodlad\|first=John R.\|last2=Krajewski\|first2=Andrew S.\|last3=Batstone\|first3=Paul J.\|last4=McKay\|first4=Pam\|last5=White\|first5=Jo M.\|last6=Benton\|first6=E. Claire\|last7=Kavanagh\|first7=Gina M.\|last8=Lucraft\|first8=Helen H.\|last9=Scotland and Newcastle Lymphoma Group\|date=2003-12\|title=Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes\|url=https://pubmed.ncbi.nlm.nih.gov/14657713\|journal=The American Journal of Surgical Pathology\|volume=27\|issue=12\|pages=1538–1545\|doi=10.1097/00000478-200312000-00006\|issn=0147-5185\|pmid=14657713}}</ref>.		The t(14;18)(q32;q21), ''IGH''/''BCL2'' translocation, the genetic hallmark of nodal follicular lymphoma, is rare in primary cutaneous follicle center lymphoma<ref name=":0">{{Cite journal\|last=Gángó\|first=Ambrus\|last2=Bátai\|first2=Bence\|last3=Varga\|first3=Martin\|last4=Kapczár\|first4=Dóra\|last5=Papp\|first5=Gergő\|last6=Marschalkó\|first6=Márta\|last7=Kuroli\|first7=Enikő\|last8=Schneider\|first8=Tamás\|last9=Csomor\|first9=Judit\|date=2018-10\|title=Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein\|url=https://pubmed.ncbi.nlm.nih.gov/29858685\|journal=Virchows Archiv: An International Journal of Pathology\|volume=473\|issue=4\|pages=453–462\|doi=10.1007/s00428-018-2384-3\|issn=1432-2307\|pmid=29858685}}</ref><ref>{{Cite journal\|last=Goodlad\|first=John R.\|last2=Krajewski\|first2=Andrew S.\|last3=Batstone\|first3=Paul J.\|last4=McKay\|first4=Pam\|last5=White\|first5=Jo M.\|last6=Benton\|first6=E. Claire\|last7=Kavanagh\|first7=Gina M.\|last8=Lucraft\|first8=Helen H.\|last9=Scotland and Newcastle Lymphoma Group\|date=2003-12\|title=Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes\|url=https://pubmed.ncbi.nlm.nih.gov/14657713\|journal=The American Journal of Surgical Pathology\|volume=27\|issue=12\|pages=1538–1545\|doi=10.1097/00000478-200312000-00006\|issn=0147-5185\|pmid=14657713}}</ref>.
Line 182:		Line 188:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 189:		Line 198:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	*Chromosomal abnormalities in PCFCL involving ''BCL2'' or ''MALT1'' do not correlate with a poor prognosis<ref name=":2" />.		*Chromosomal abnormalities in PCFCL involving ''BCL2'' or ''MALT1'' do not correlate with a poor prognosis<ref name=":2" />.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 241:		Line 253:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 254:		Line 266:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 278:		Line 293:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	In a study of the genetic abnormalities of primary cutaneous follicle center lymphoma, 1p36 deletion was reported to occur in 22% (5/21) and ''BCL2'' gene break in 10% (2/20) of the cases. ''TNFRSF14'' nonsense and missense mutations were detected in 4/17 (23.5%) cases with concomitant 1p36 deletion in 2 cases. In 43% (9/21) of the cases, high EZH2 protein expression with a ''BCL2'' negative phenotype was detected<ref name=":0" />. In another study that investigated 57 patients with PCFCL, 1 case was found to have ''BCL2'' chromosomal amplification, 4 cases had ''IGH''/''BCL2 translocation'', and 1 case had ''IGH/MALT1'' translocation<ref>{{Cite journal\|last=Abdul-Wahab\|first=Alya\|last2=Tang\|first2=Soo-Yong\|last3=Robson\|first3=Alistair\|last4=Morris\|first4=Stephen\|last5=Agar\|first5=Nita\|last6=Wain\|first6=E. Mary\|last7=Child\|first7=Fiona\|last8=Scarisbrick\|first8=Julia\|last9=Neat\|first9=Michael\|date=2014-06\|title=Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis\|url=https://doi.org/10.1016/j.jaad.2014.01.862\|journal=Journal of the American Academy of Dermatology\|volume=70\|issue=6\|pages=1010–1020\|doi=10.1016/j.jaad.2014.01.862\|issn=0190-9622}}</ref>. In a case report of an aggressive PCFCL, ''c-MYC'' translocation and ''CDKN2A'' (9p21) deletion were detected<ref>{{Cite journal\|last=Tsang\|first=Hamilton C.\|last2=Mathew\|first2=Susan\|last3=Magro\|first3=Cynthia M.\|date=2017-03\|title=An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature\|url=https://pubmed.ncbi.nlm.nih.gov/27759694\|journal=The American Journal of Dermatopathology\|volume=39\|issue=3\|pages=e44–e49\|doi=10.1097/DAD.0000000000000738\|issn=1533-0311\|pmid=27759694}}</ref>.		In a study of the genetic abnormalities of primary cutaneous follicle center lymphoma, 1p36 deletion was reported to occur in 22% (5/21) and ''BCL2'' gene break in 10% (2/20) of the cases. ''TNFRSF14'' nonsense and missense mutations were detected in 4/17 (23.5%) cases with concomitant 1p36 deletion in 2 cases. In 43% (9/21) of the cases, high EZH2 protein expression with a ''BCL2'' negative phenotype was detected<ref name=":0" />. In another study that investigated 57 patients with PCFCL, 1 case was found to have ''BCL2'' chromosomal amplification, 4 cases had ''IGH''/''BCL2 translocation'', and 1 case had ''IGH/MALT1'' translocation<ref>{{Cite journal\|last=Abdul-Wahab\|first=Alya\|last2=Tang\|first2=Soo-Yong\|last3=Robson\|first3=Alistair\|last4=Morris\|first4=Stephen\|last5=Agar\|first5=Nita\|last6=Wain\|first6=E. Mary\|last7=Child\|first7=Fiona\|last8=Scarisbrick\|first8=Julia\|last9=Neat\|first9=Michael\|date=2014-06\|title=Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis\|url=https://doi.org/10.1016/j.jaad.2014.01.862\|journal=Journal of the American Academy of Dermatology\|volume=70\|issue=6\|pages=1010–1020\|doi=10.1016/j.jaad.2014.01.862\|issn=0190-9622}}</ref>. In a case report of an aggressive PCFCL, ''c-MYC'' translocation and ''CDKN2A'' (9p21) deletion were detected<ref>{{Cite journal\|last=Tsang\|first=Hamilton C.\|last2=Mathew\|first2=Susan\|last3=Magro\|first3=Cynthia M.\|date=2017-03\|title=An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature\|url=https://pubmed.ncbi.nlm.nih.gov/27759694\|journal=The American Journal of Dermatopathology\|volume=39\|issue=3\|pages=e44–e49\|doi=10.1097/DAD.0000000000000738\|issn=1533-0311\|pmid=27759694}}</ref>.

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 317:		Line 335:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 332:		Line 350:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 357:		Line 378:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	''BCL2-''mediated apoptosis pathway and NF-κB pathway		''BCL2-''mediated apoptosis pathway and NF-κB pathway
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Bailey.Glen at 22:28, 6 September 2024

2024-09-06T22:28:46Z

← Older revision		Revision as of 17:28, 6 September 2024
Line 15:		Line 15:
	__TOC__		__TOC__

	==~~Cancer Category / Type~~==		==WHO Classification of Disease==

	*[[HAEM4:Mature B-~~Cell Neoplasms]]~~		{\| class="wikitable"
			!Structure
	~~==Cancer Sub~~-~~Classification /~~ Subtype==		!Disease
			\|-
	*Primary Cutaneous Follicle Center Lymphoma		\|Book
			\|Haematolymphoid Tumours (5th ed.)
			\|-
			\|Category
			\|B-cell lymphoid proliferations and lymphomas
			\|-
			\|Family
			\|Mature B-cell neoplasms
			\|-
			\|Type
			\|Cutaneous follicle centre lymphoma
			\|-
			\|Subtype(s)
			\|Primary cutaneous follicle centre lymphoma
			\|}

	==Definition / Description of Disease==		==Definition / Description of Disease==

Bailey.Glen at 22:09, 6 September 2024

2024-09-06T22:09:53Z

Show changes

Bailey.Glen at 19:38, 13 December 2023

2023-12-13T19:38:16Z

← Older revision		Revision as of 14:38, 13 December 2023
Line 6:		Line 6:
	<blockquote class='blockedit'>{{Box-round\|title=HAEM5 Conversion Notes\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Primary Cutaneous Follicle Centre Lymphoma]].		<blockquote class='blockedit'>{{Box-round\|title=HAEM5 Conversion Notes\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Primary Cutaneous Follicle Centre Lymphoma]].
	}}</blockquote>		}}</blockquote>

			<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>

	==Primary Author(s)*==		==Primary Author(s)*==